Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | RET E632_L633del |
Therapy | Selpercatinib |
Indication/Tumor Type | medullary thyroid carcinoma |
Response Type | conflicting |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET E632_L633del | medullary thyroid carcinoma | conflicting | Selpercatinib | Case Reports/Case Series | Actionable | In a Phase I trial, Retevmo (selpercatinib) resulted in a partial response in the target lesions and stable disease in the non-target lesions in a patient with sporadic medullary thyroid cancer harboring RET E632_L633del, and treatment continued for at least 17 months (PMID: 35616103; NCT03906331). | 35616103 |
RET E632_L633del | medullary thyroid carcinoma | conflicting | Selpercatinib | Case Reports/Case Series | Actionable | In a clinical case study, Retevmo (selpercatinib) treatment resulted in limited activity in a patient with medullary thyroid carcinoma harboring RET E632_L633del, with a partial response achieved at cycle 9 but significant progressive disease observed at cycle 13 (PMID: 36416226; NCT03157128). | 36416226 |
PubMed Id | Reference Title | Details |
---|---|---|
(35616103) | Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib. | Full reference... |
(36416226) | A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion. | Full reference... |